NCT03489031 (BASAL) is a clinical trial in Diabetes Mellitus, Type 1, sponsored by Associazione Medici Endocrinologi.

Who is sponsoring NCT03489031?

NCT03489031 is sponsored by Associazione Medici Endocrinologi.

What condition does NCT03489031 study?

NCT03489031 studies Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.

Is NCT03489031 still recruiting?

NCT03489031 is currently completed. Last updated 5 April 2018.

Last reviewed 2018-04-05 · How we verify

NCT03489031: BASAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Basal Insulin And Compensation Glycemic In Diabetic Patients In Basal Bolus Outpatient.

Completed Last updated 5 April 2018

What this trial tests

trial in Diabetes Mellitus, Type 1 in 1,036 participants. Completed in 31 January 2017.

Timeline

11 April 2016

Primary endpoint
30 September 2016

31 January 2017

Quick facts

Lead sponsor	Associazione Medici Endocrinologi
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,036
Start date	11 April 2016
Primary completion	30 September 2016
Estimated completion	31 January 2017

Conditions studied

Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Associazione Medici Endocrinologi

Who can join

Adults 20 to 80, any sex, with Diabetes Mellitus, Type 1 or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentric, observational, cross-sectional study in Italy. The aims are to evaluate the basal/total ratio of daily insulin dose (b/T) in diabetic outpatients type 1 (T1) and type 2 (T2) on basal-bolus regimen, by investigating whether there is a relationship with HbA1c and episodes of hypoglycemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen.
Castellano E, Attanasio R, Giagulli VA, Boriano A, et al · · 2018 · cited 5× · PMID 30918874 · DOI 10.1007/s40200-018-0358-2

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

NCT07325461 — Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 Diabetes · NA · recruiting
NCT07305805 — A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes · Phase 1 · recruiting
NCT06282055 — Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes · recruiting
NCT06325202 — Closed Loop and Education for Hypoglycemia Awareness Restoration · NA · recruiting
NCT07160816 — A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar · recruiting

Other Associazione Medici Endocrinologi trials

Trials by the same sponsor.

NCT04295031 — Metformin in Older Adults With Type 2 Diabetes (AMEMET) · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03489031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Associazione Medici Endocrinologi
Last refreshed: 5 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03489031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing